Table 4.

Univariate analyses of pre-transplant factors and the impact on overall survival and relapse-free survival from day 28, n = 106.

Variable	N	Overall survival		Relapse-free survival
		HR (95% CI)	P-value	HR (95%CI)	P-value
Recipient age
Per 10 years older	–	1.15 (0.84–1.59)	0.39	1.04 (0.80–1.36)	0.76
Disease type
AML/MDS	70	1.00	0.38	1.00	0.36
Other	36	1.42 (0.66–3.06)		1.37 (0.70–2.68)
Donor age
<30 years	60	1.00		1.00
>30 years	46	2.12 (0.98–4.57)	0.06	2.58 (1.32–5.04)	0.01
Donor type
Matched related donor	23	1.00		1.00
Matched unrelated donor	83	1.50 (0.52–4.36)	0.45	0.83 (0.38–1.84)	0.65
Graft source
PBSC	91	1.00		1.00
BM	15	0.99 (0.34–2.87)	0.99	0.88 (0.34–2.26)	0.79
Conditioning regimen
Myeloablative	49	1.00		1.00
Non-myeloablative	57	2.23 (0.98–5.10)	0.06	1.80 (0.92–3.55)	0.09
ATG
No	94	1.00		1.00
Yes	12	0.69 (0.16–2.93)	0.62	1.51	0.40
CMV donor
Negative	58	1.00		1.00
Positive	48	1.60 (0.75–3.43)	0.22	1.43 (0.75–2.74)	0.28
CMV recipient
Negative	33	1.00		1.00
Positive	73	0.88 (0.40–1.97)	0.76	0.88 (0.44–1.76)	0.72
Disease risk index*
Low	10			1.00
Intermediate	85			5.05 (0.69–36.98)
High	11	–		4.11 (0.46–36.92)	0.27

Hazard ratios are of death in overall survival and of death or relapse in relapse-free survival. AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CMV, cytomelagovirus; DRI, Disease Risk Index.

^*Disease Risk Index, as there were no deaths in the low risk group during the observation time, no estimate of this variable is included for OS.